Problems in pharmacological evaluation of patients with paroxysmal atrial fibrillation: Clinical analysis of more than 100 consecutive patients

Internal Medicine

Volumn 37, Issue 12, 1998, Pages 1005-1008

  Iga, Kanji ^a   Izumi, Chisato ^a   Nakano, Atsushi ^a   Sakanoue, Yuji ^a   Miyamoto, Tadashi ^a   Kitaguchi, Shouji ^a   Himura, Yoshihiro ^a   Gen, Hiromitsu ^a   Konishi, Takashi ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

Drug efficacy; Holter monitoring; Symptoms

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MALE; MIDDLE AGED; PAROXYSMAL TACHYCARDIA; PATHOPHYSIOLOGY; QUESTIONNAIRE; REPRODUCIBILITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TACHYCARDIA, PAROXYSMAL; TREATMENT OUTCOME;

EID: 0032240968     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.1005     Document Type: Review

References (11)

1. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: A nine-month follow-up of more than 500 patients. Am J Cardiol 70:44A-49A, 1992.
2. Lau CP, Leung WH, Wong CK. A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 124: 645-650, 1992.
3. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 108: 355-358, 1995.
4. Zaman AG, Alamgir F, Richens T, William R, Rothman MT, Mills PG. The role of signal averaged P wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary artery bypass surgery. Heart 77: 527-531, 1997.
5. Lown B, Desilva RA. Roles of psychological stress and autonomic nervous system changes in provocation of ventricular premature complexes. Am J Cardiol 41: 979-985, 1979.
6. Bayes de Luna A, Gayes Genis A, Guindo J, et al. Mechanism favoring and triggering atrial fibrillation. Arch Mal Coeur Vaiss 87: 19-25, 1994 (in French).
7. Hayakawa H, Olsu F, Sato T, Iida N, Suzuki T, Nejima J. Evaluation of effects of antiarrhythmics on ventricular premature contraction. Jpn Circ J47: 132-138, 1983.
8. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89: 224-227, 1994.
9. Wolk R, Kulakowski P, Karczmarewicz S, et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Int J Cardiol 54: 207-211, 1996.
10. Kinlay S, Leitch JW, Neil A, Chapman BL, Hardy DB, Fletcher PJ. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holler monitoring in patients with palpitations. A controlled clinical trial. Ann Intern Med 124: 16-20, 1996.
11. Bhandari AK, Anderson JL, Gilbert EM, et al and The Flecainide Supraventricular Tachycardia Study Group. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: A transtelephonic monitoring study. Am Heart J 124: 381, 1992.